Is transcranial magnetic stimulation (TMS) FDA‑approved for the treatment of dementia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

TMS is NOT FDA-Approved for Dementia

Transcranial magnetic stimulation (TMS) does not have FDA approval for the treatment of dementia or cognitive impairment associated with dementia. While TMS is FDA-approved for other conditions including treatment-resistant depression, OCD, and smoking cessation 1, it remains investigational for dementia.

Current FDA-Approved Treatments for Dementia

The only FDA-approved pharmacologic treatments for dementia are:

  • Cholinesterase inhibitors: donepezil, galantamine, rivastigmine (and tacrine, though no longer used)
  • Memantine: an NMDA receptor antagonist
  • Aducanumab: recently approved for early-stage Alzheimer's disease, though its use remains controversial with limited efficacy evidence 2

These medications are specifically approved for Alzheimer's disease, though they are used off-label for other dementias in clinical practice 3, 4, 3.

TMS Status in Dementia: Investigational Only

TMS for dementia remains in the research phase. Recent evidence shows:

  • Clinical trials are ongoing to assess TMS efficacy in cognitive decline and Alzheimer's disease 1, 5, 6
  • High-frequency repetitive TMS (rTMS) targeting the dorsolateral prefrontal cortex has shown preliminary improvements in memory, executive function, and attention in research settings 6, 7
  • Studies report rTMS is generally safe and tolerable with mild adverse effects (transient headache, scalp discomfort) 7
  • Evidence suggests potential benefits when delivered at 5-20 Hz for 4-12 weeks, but substantial heterogeneity in protocols, small sample sizes, and short follow-up periods prevent definitive conclusions 7

Critical Limitations

TMS is not ready for routine dementia care because:

  • Marked protocol heterogeneity limits identification of optimal parameters
  • Small sample sizes and short follow-up in existing trials
  • No standardized treatment protocols established
  • Lack of long-term efficacy data
  • No FDA approval or regulatory clearance for this indication 6, 7

Clinical Implications

If a patient or family asks about TMS for dementia:

  • Explain it is not FDA-approved and remains experimental
  • Direct them to FDA-approved medications (cholinesterase inhibitors, memantine) as first-line treatment 4
  • Consider clinical trial enrollment if appropriate research protocols are available
  • Emphasize that high-quality, person-centered care and psychosocial interventions remain the foundation of dementia management 2

Bottom line: TMS shows promise in research settings but lacks regulatory approval and sufficient evidence for clinical use in dementia. Stick with FDA-approved pharmacologic treatments and evidence-based non-pharmacologic interventions.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.